Skip to content

Jaeger V-178500Recalls & reported problems

Jaeger Medical GmbH · Vyntus BODY · Class 2

Adverse event reports
1
Deaths reported
0
Injuries reported
0
Recalls naming it
0

Summary

The FDA's MAUDE database contains 1 adverse event report that list this exact device (DI 04250892908304), received between Jan 8, 2026 and Jan 8, 2026 — classified as 1 malfunction.

The most frequently reported specific device problem is “Inaccurate Flow Rate” (1 report).

Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. How this data works · Data updated Oct 13, 2026.

Reports received per month

Nov 2023: 0 reportsDec 2023: 0 reportsJan 2024: 0 reportsFeb 2024: 0 reportsMar 2024: 0 reportsApr 2024: 0 reportsMay 2024: 0 reportsJun 2024: 0 reportsJul 2024: 0 reportsAug 2024: 0 reportsSep 2024: 0 reportsOct 2024: 0 reportsNov 2024: 0 reportsDec 2024: 0 reportsJan 2025: 0 reportsFeb 2025: 0 reportsMar 2025: 0 reportsApr 2025: 0 reportsMay 2025: 0 reportsJun 2025: 0 reportsJul 2025: 0 reportsAug 2025: 0 reportsSep 2025: 0 reportsOct 2025: 0 reportsNov 2025: 0 reportsDec 2025: 0 reportsJan 2026: 1 reportsFeb 2026: 0 reportsMar 2026: 0 reportsApr 2026: 0 reportsMay 2026: 0 reportsJun 2026: 0 reportsJul 2026: 0 reportsAug 2026: 0 reportsSep 2026: 0 reportsOct 2026: 0 reports2024202520261
Last 36 months. The most recent month may be incomplete.

Most reported problems

Device problems

  • Inaccurate Flow Rate1

Patient problems

  • Cough1
  • Loss of consciousness1

Recent adverse event reports

The 1 most recent of 1 reports, in the reporter's own words as published by the FDA.

  • MalfunctionJan 8, 2026Inaccurate Flow Rate

    IT WAS REPORTED THAT DURING RECENT HISTAMINE PROVOCATION TESTING USING THE VYNTUS BODY APS SYSTEM, TWO PATIENTS EXPERIENCED DISCOMFORT DURING BRONCHIAL PROVOCATION TESTING WITH HISTAMINE. THE HISTAMINE CONCENTRATION USED WAS 16 MG/ML AND THE PROVOCATION PROTOCOL CONSISTED OF FOUR STEPS OF 0.015, 0.045, 0.18 AND 0.72. ONE PATIENT EXPERIENCED HOT FLUSHES AND DIZZINESS AND DEVELOPED BRONCHOCONSTRICTION WITH A SIGNIFICANT REDUCTION IN FEV, RESULTING IN A POSITIVE BRONCHIAL CHALLENGE RESPONSE. ANOTHER PATIENT DID NOT SHOW BRONCHOCONSTRICTION BUT FAINTED IN THE TEST BOOTH FOR A FEW SECONDS. NO FURTHER SYMPTOMS BEYOND DISCOMFORT, DIZZINESS AND FAINTING WERE REPORTED. IN ADDITION, CONCERNS WERE RAISED REGARDING THE NEBULIZER OUTPUT DURING USE OF THE APS SYSTEM. MEASUREMENTS PERFORMED ON SITE BY THE CUSTOMER USING SALINE SOLUTION AND A PRECISION SCALE INDICATED HIGHER NEBULIZER OUTPUT VALUES THAN EXPECTED BASED ON AVAILABLE TECHNICAL INFORMATION. THIS LED TO UNCERTAINTY REGARDING THE AMOUNT OF SUBSTANCE ADMINISTERED TO PATIENTS DURING BRONCHIAL PROVOCATION TESTING. FURTHERMORE, CONCERNS WERE EXPRESSED ABOUT THE RELIABILITY OF NEBULIZER PERFORMANCE WHEN DIFFERENT FILLING VOLUMES ARE USED. IT

    Patient problems: Cough; Loss of consciousness

    MAUDE report 24001206 ↗

Other Calculator, Pulmonary Function Data devices

All Calculator, Pulmonary Function Data devices →

Sources: FDA GUDID, MAUDE and Medical Device Recalls via openFDA. openFDA data is not validated for clinical or regulatory use.